FDA approves Lundbeck´s Vyepti[TM] (eptinezumab-jjmr) - the first and only intravenous preventive treatment for migraine
(WorldNews Denmark)

FDA approves Lundbeck`s Vyepti[TM] (eptinezumab-jjmr) - the first and only intravenous preventive treatment for migraine · In two clinical studies (PROMISE-1 in episodic migraine and PROMISE-2 in chronic migraine), Vyepti met its primary endpoint: decrease in mean monthly migraine days (MMD) over months 1-3.[i] · A treatment benefit over placebo was observed for both doses of Vyepti as early as day 1 post-infusion, and the percentage of patients experiencing a migraine was lower for Vyepti than with placebo for most of the first 7 days.[i] · In both studies, Vyepti demonstrated a sustained reduction of MMD through the second dose (month 6).[i] Valby, Denmark, February 22, 2020 - H. Lundbeck...